What is SomaLogic?
SomaLogic operates as a commercial-stage proteomics company, providing a sophisticated platform designed for high-throughput analysis with broad proteome coverage. By achieving low limits of detection and high reproducibility at reduced costs, the firm addresses critical bottlenecks in biological research and clinical diagnostics. Its technology is instrumental in enabling researchers to decode the complex protein signatures that underpin human health and disease, positioning the company as a vital infrastructure provider within the broader life sciences ecosystem.
How much funding has SomaLogic raised?
SomaLogic has raised a total of $1.3B across 11 funding rounds:
Private Equity
$10M
Unspecified
$1M
Private Equity
$16.5M
Private Equity
$60.5M
Private Equity
$163M
Private Equity
$44.9M
Private Equity
$200M
Debt
$2M
Series A
$214M
Stock Offering
$630M
Private Equity (2013): $10M, investors not publicly disclosed
Unspecified (2014): $1M supported by Bill & Melinda Gates Foundation
Private Equity (2014): $16.5M, investors not publicly disclosed
Private Equity (2016): $60.5M backed by Visium Healthcare Partners
Private Equity (2016): $163M, investors not publicly disclosed
Private Equity (2017): $44.9M, investors not publicly disclosed
Private Equity (2018): $200M supported by Madryn Asset Management, iCarbonX, Quest Diagnostics, Visium Healthcare Partners, Otsuka Pharmaceutical, ProQuest Investments, and Nan Fung Life Sciences
Debt (2020): $2M featuring PPP
Series A (2020): $214M backed by Millennium Management, Casdin Capital, Fiscus Ventures, Mossrock Capital, Foresite Capital, Soleus Capital, Janus Henderson Investors, Logos Capital, Madryn Asset Management, Boston Millennia Partners, T. Rowe Price Associates, Revelation Partners, Farallon Capital Management, Monashee Investment Management, Remagine Ventures, Blue Water Life Science Advisors, Ziff Capital Healthcare Ventures, and Redmile Group
Stock Issuance/Offering (2021): $630M with participation from T. Rowe Price, Corvex Management, SB Management, Casdin Capital, and Janus Henderson Investors
Key Investors in SomaLogic
T. Rowe Price
A global asset management organization providing investment solutions across equities and multi-asset strategies, known for its commitment to active management and fundamental research.
Casdin Capital
An investment firm focused on the next generation of life science innovation, with a specialized portfolio in diagnostics and molecular information.
Foresite Capital
A multi-stage investment firm that utilizes a data science-driven approach to transform healthcare and biotechnology by funding companies at the intersection of biology and big data.
What's next for SomaLogic?
With the recent strategic investment, SomaLogic is well-positioned to accelerate its commercial expansion and deepen its penetration into clinical and pharmaceutical markets. The company is expected to leverage this capital to enhance its platform capabilities, potentially expanding its diagnostic menu and strengthening its data-driven insights. As the firm moves forward, the focus will likely shift toward scaling operations to meet the growing demand for precision medicine tools, while maintaining its commitment to high-fidelity, cost-effective proteomic solutions that empower global healthcare innovation.
See full SomaLogic company page
